Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Cash & Current Investments (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Cash & Current Investments for 7 consecutive years, with $848.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Current Investments rose 73.56% to $848.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $848.3 million, a 73.56% increase, with the full-year FY2025 number at $848.3 million, up 73.56% from a year prior.
  • Cash & Current Investments was $848.3 million for Q4 2025 at Kymera Therapeutics, up from $505.7 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $848.3 million in Q4 2025 to a low of $33.7 million in Q1 2022.
  • A 5-year average of $448.3 million and a median of $462.2 million in 2021 define the central range for Cash & Current Investments.
  • Peak YoY movement for Cash & Current Investments: tumbled 89.89% in 2022, then surged 1076.52% in 2023.
  • Kymera Therapeutics' Cash & Current Investments stood at $442.4 million in 2021, then dropped by 7.97% to $407.2 million in 2022, then fell by 7.93% to $374.9 million in 2023, then soared by 30.37% to $488.7 million in 2024, then skyrocketed by 73.56% to $848.3 million in 2025.
  • Per Business Quant, the three most recent readings for KYMR's Cash & Current Investments are $848.3 million (Q4 2025), $505.7 million (Q3 2025), and $665.4 million (Q2 2025).